Cargando…
Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial
BACKGROUND: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237027/ https://www.ncbi.nlm.nih.gov/pubmed/32281393 http://dx.doi.org/10.1161/CIRCEP.119.008280 |
_version_ | 1783536253649551360 |
---|---|
author | Wilkoff, Bruce L. Boriani, Giuseppe Mittal, Suneet Poole, Jeanne E. Kennergren, Charles Corey, G. Ralph Love, John C. Augostini, Ralph Faerestrand, Svein Wiggins, Sherman S. Healey, Jeff S. Holbrook, Reece Lande, Jeffrey D. Lexcen, Daniel R. Willey, Sarah Tarakji, Khaldoun G. |
author_facet | Wilkoff, Bruce L. Boriani, Giuseppe Mittal, Suneet Poole, Jeanne E. Kennergren, Charles Corey, G. Ralph Love, John C. Augostini, Ralph Faerestrand, Svein Wiggins, Sherman S. Healey, Jeff S. Holbrook, Reece Lande, Jeffrey D. Lexcen, Daniel R. Willey, Sarah Tarakji, Khaldoun G. |
author_sort | Wilkoff, Bruce L. |
collection | PubMed |
description | BACKGROUND: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. METHODS: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. RESULTS: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P<0.001), an effect that sustained beyond 12 months (hazard ratio through all follow-up, 2.30 [95% CI, 1.29–4.07]; P=0.004). Quality of life was reduced (P=0.004) and did not normalize for 6 months. Disruptions in CIED therapy were experienced in 36% of infections for a median duration of 184 days. Mean costs were $55 547±$45 802 for the hospital, $26 867±$14 893, for medicare fee for service and $57 978±$29 431 for Medicare Advantage (mean hospital margin of −$30 828±$39 757 for medicare fee for service and −$6055±$45 033 for medicare advantage). Mean out-of-pocket costs for patients were $2156±$1999 for medicare fee for service, and $1658±$1250 for medicare advantage. CONCLUSIONS: This large, prospective analysis corroborates and extends understanding of the impact of CIED infections as seen in real-world datasets. CIED infections severely impact mortality, quality of life, healthcare utilization, and cost in the US healthcare system. REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02277990 |
format | Online Article Text |
id | pubmed-7237027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-72370272020-06-15 Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial Wilkoff, Bruce L. Boriani, Giuseppe Mittal, Suneet Poole, Jeanne E. Kennergren, Charles Corey, G. Ralph Love, John C. Augostini, Ralph Faerestrand, Svein Wiggins, Sherman S. Healey, Jeff S. Holbrook, Reece Lande, Jeffrey D. Lexcen, Daniel R. Willey, Sarah Tarakji, Khaldoun G. Circ Arrhythm Electrophysiol Original Articles BACKGROUND: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. METHODS: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. RESULTS: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P<0.001), an effect that sustained beyond 12 months (hazard ratio through all follow-up, 2.30 [95% CI, 1.29–4.07]; P=0.004). Quality of life was reduced (P=0.004) and did not normalize for 6 months. Disruptions in CIED therapy were experienced in 36% of infections for a median duration of 184 days. Mean costs were $55 547±$45 802 for the hospital, $26 867±$14 893, for medicare fee for service and $57 978±$29 431 for Medicare Advantage (mean hospital margin of −$30 828±$39 757 for medicare fee for service and −$6055±$45 033 for medicare advantage). Mean out-of-pocket costs for patients were $2156±$1999 for medicare fee for service, and $1658±$1250 for medicare advantage. CONCLUSIONS: This large, prospective analysis corroborates and extends understanding of the impact of CIED infections as seen in real-world datasets. CIED infections severely impact mortality, quality of life, healthcare utilization, and cost in the US healthcare system. REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02277990 Lippincott Williams & Wilkins 2020-04-12 /pmc/articles/PMC7237027/ /pubmed/32281393 http://dx.doi.org/10.1161/CIRCEP.119.008280 Text en © 2020 American Heart Association, Inc. Circulation: Arrhythmia and Electrophysiology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. |
spellingShingle | Original Articles Wilkoff, Bruce L. Boriani, Giuseppe Mittal, Suneet Poole, Jeanne E. Kennergren, Charles Corey, G. Ralph Love, John C. Augostini, Ralph Faerestrand, Svein Wiggins, Sherman S. Healey, Jeff S. Holbrook, Reece Lande, Jeffrey D. Lexcen, Daniel R. Willey, Sarah Tarakji, Khaldoun G. Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title | Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title_full | Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title_fullStr | Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title_full_unstemmed | Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title_short | Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial |
title_sort | impact of cardiac implantable electronic device infection: a clinical and economic analysis of the wrap-it trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237027/ https://www.ncbi.nlm.nih.gov/pubmed/32281393 http://dx.doi.org/10.1161/CIRCEP.119.008280 |
work_keys_str_mv | AT wilkoffbrucel impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT borianigiuseppe impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT mittalsuneet impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT poolejeannee impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT kennergrencharles impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT coreygralph impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT lovejohnc impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT augostiniralph impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT faerestrandsvein impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT wigginsshermans impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT healeyjeffs impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT holbrookreece impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT landejeffreyd impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT lexcendanielr impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT willeysarah impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial AT tarakjikhaldoung impactofcardiacimplantableelectronicdeviceinfectionaclinicalandeconomicanalysisofthewrapittrial |